Andrew Skinner

Dr. Andrew Skinner

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
SRSarah N Redmond
Sarah N Redmond
JCJennifer L Cadnum
Jennifer L Cadnum
AJAnnette L Jencson
Annette L Jencson
CKClaire E Kaple
Claire E Kaple
BWBrigid M Wilson
Brigid M Wilson
CDCurtis J Donskey
Curtis J Donskey
Background: There have been several recent reports of Clostridioides difficile infection (CDI) due to isolates with reduced fidaxomicin susceptibility (minimum inhibitory concentration [MIC] ≥ 2 µg/mL). However, the clinical implications are uncertain because fidaxomicin achieves high concentrations in the intestinal tract. Methods: In an acute care hospital, we conducted a 3-year cohort study of patients with CDI to determine the frequency of infection with isolates with reduced fidaxomicin susceptibility and the impact on response to fidaxomicin treatment. Stool specimens were cultured for C. difficile, and susceptibility testing was performed using agar dilution. Whole-genome sequencing was used to identify mutations associated with reduced fidaxomicin susceptibility and to determine relatedness of isolates. For genomically related susceptible and reduced susceptibility isolates from the same patient, we compared rates of growth, sporulation, and toxin production. Results: Of 108 fidaxomicin-treated patients, 6 (5.6%) were infected with isolates that possessed reduced fidaxomicin susceptibility (MICs 8–32 µg/mL), including 3 with initially susceptible isolates followed by clinical failure with subsequent recovery of genomically related isolates with reduced susceptibility. Isolates with reduced fidaxomicin susceptibility harbored mutations in RNA polymerase associated with reduced susceptibility and exhibited reduced toxin production, and 20% to 40% of isolates tested had reduced growth and/or sporulation in comparison with susceptible isolates. Three patients were infected with genomically indistinguishable ribotype 097 isolates with reduced fidaxomicin susceptibility. Conclusions: Our findings highlight the potential for the emergence on therapy of clinically relevant reduced fidaxomicin susceptibility in C. difficile and its spread via transmission to other patients.

14 March 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ASAndrew Skinner
Andrew Skinner
XTXing Tan
Xing Tan
BSBenjamin D Sirbu
Benjamin D Sirbu
LDLarry H Danziger
Larry H Danziger
DGDale N Gerding
Dale N Gerding
SJStuart Johnson
Stuart Johnson
We treated 46 patients with multiple recurrent Clostridioides difficile infections (mrCDI) using a tapered-pulsed (T-P) fidaxomicin regimen, the majority of whom failed prior T-P vancomycin treatment. Sustained clinical response rates at 30 and 90 days were 74% (34/46) and 61% (28/46). T-P fidaxomicin shows promise for management of mrCDI.

13 April 2023 in Microbiology Spectrum
Verified
Journal Article
Closed access
SSSusan P. Sambol
Susan P. Sambol
ASAndrew Skinner
Andrew Skinner
FSFidel Serna-Perez
Fidel Serna-Perez
BOBenjamin Owen
Benjamin Owen
DGDale N. Gerding
Dale N. Gerding
SJStuart Johnson
Stuart Johnson
NTCD-M3 is a novel live biotherapeutic, that has been shown in a Phase 2 clinical trial to prevent recurrence of C. difficile infection (CDI) when administered shortly after antibiotic treatment of the initial CDI episode. Fidaxomicin was not, however, in widespread use at the time this study was conducted.

30 November 2023 in Journal of Clinical Gastroenterology
Verified
Journal Article
Open access
PFPaul Feuerstadt
Paul Feuerstadt
CCCarl V. Crawford
Carl V. Crawford
XTXing Tan
Xing Tan
VPVictoria Pokhilko
Victoria Pokhilko
LBLindy Bancke
Lindy Bancke
ASAndrew Skinner
Andrew Skinner
Goals: To assess fecal microbiota, live-jslm (REBYOTA, abbreviated as RBL, formerly RBX2660) efficacy and safety in participants grouped by recurrent Clostridioides difficile infection (rCDI) risk factors and treatment-related variables. Background: RBL is the first microbiota-based live biotherapeutic approved by the US Food and Drug Administration for the prevention of rCDI in adults after antibiotic treatment for rCDI. Study: Treatment success rates across subgroups for PUNCH CD3 (NCT03244644) were estimated using a Bayesian hierarchical model, borrowing data from PUNCH CD2 (NCT02299570). Treatment-emergent adverse events were summarized for the double-blind treatment period within 8 weeks. Results: Treatment differences between RBL and placebo at 8 weeks were similar to the total population for most subgroups. Treatment effect sizes were similar between CDI tests, higher for oral vancomycin courses >14 days versus ≤14 days and higher for antibiotic washout periods of 3 days versus ≤2 days. The largest reductions in the rate of rCDI with RBL versus placebo were observed for participants with a 3-day CDI antibiotic washout period and participants with ≥4 previous CDI episodes. Most RBL-treated participants experienced TEAEs that were mild or moderate in severity and related to preexisting conditions. Conclusion: This analysis provides further evidence of RBL efficacy and safety across subgroups, including those at high risk for rCDI.

30 December 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAndrew Skinner
Andrew Skinner
SPS. Tyler Phillips
S. Tyler Phillips
MMMichelle M. Merrigan
Michelle M. Merrigan
KOKevin J. O’leary
Kevin J. O’leary
SSSusan P. Sambol
Susan P. Sambol
SJStuart Johnson
Stuart Johnson
Most pathogenic strains of C. difficile possess two large molecular weight single unit toxins with four similar functional domains. The toxins disrupt the actin cytoskeleton of intestinal epithelial cells leading to loss of tight junctions, which ultimately manifests as diarrhea in the host. While initial studies of purified toxins in animal models pointed to toxin A (TcdA) as the main virulence factor, animal studies using isogenic mutants demonstrated that toxin B (TcdB) alone was sufficient to cause disease. In addition, the natural occurrence of TcdA−/TcdB+ (TcdA−/B+)mutant strains was shown to be responsible for cases of C. difficile infection (CDI) with symptoms identical to CDI caused by fully toxigenic (A+/B+) strains. Identification of these cases was delayed during the period when clinical laboratories were using immunoassays that only detected TcdA (toxA EIA). Our hospital laboratory at the time performed culture as well as toxA EIA on patient stool samples. A total of 1.6% (23/1436) of all clinical isolates recovered over a 2.5-year period were TcdA−/B+ variants, the majority of which belonged to the restriction endonuclease analysis (REA) group CF and toxinotype VIII. Despite reports of serious disease due to TcdA−/B+ CF strains, these infections were typically mild, often not requiring specific treatment. While TcdB alone may be sufficient to cause disease, clinical evidence suggests that both toxins have a role in disease.

1 February 2020 in Emerging Infectious Diseases
Verified
Journal Article
Open access
ASAndrew Skinner
Andrew Skinner
LPLaurica Petrella
Laurica Petrella
FSFarida Siddiqui
Farida Siddiqui
SSSusan P. Sambol
Susan P. Sambol
CGChristopher A. Gulvik
Christopher A. Gulvik
SJStuart Johnson
Stuart Johnson
During a surveillance study of patients in a long-term care facility and the affiliated acute care hospital in the United States, we identified a Clostridioides difficile strain related to the epidemic PCR ribotype (RT) 027 strain associated with hospital outbreaks of severe disease. Fifteen patients were infected with this strain, characterized as restriction endonuclease analysis group DQ and RT591. Like RT027, DQ/RT591 contained genes for toxin B and binary toxin CDT and a tcdC gene of identical sequence. Whole-genome sequencing and multilocus sequence typing showed that DQ/RT591 is a member of the same multilocus sequence typing clade 2 as RT027 but in a separate cluster. DQ/RT591 produced a similar cytopathic effect as RT027 but showed delayed toxin production in vitro. DQ/RT591 was susceptible to moxifloxacin but highly resistant to clindamycin. Continued surveillance is warranted for this clindamycin-resistant strain that is related to the fluoroquinolone-resistant epidemic RT027 strain.